Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Rating) has been assigned a consensus recommendation of “Buy” from the eleven brokerages that are presently covering the company, MarketBeat.com reports. Eight investment analysts have rated the stock with a buy rating. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $44.60.
A number of equities analysts recently weighed in on VRDN shares. Cowen began coverage on shares of Viridian Therapeutics in a research report on Monday, December 19th. They set an “outperform” rating for the company. Credit Suisse Group initiated coverage on shares of Viridian Therapeutics in a research note on Friday, December 16th. They issued an “outperform” rating and a $51.00 price target for the company. B. Riley increased their price objective on Viridian Therapeutics from $40.00 to $46.00 in a research note on Tuesday, January 10th. Cowen began coverage on Viridian Therapeutics in a research note on Monday, December 19th. They issued an “outperform” rating and a $45.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $35.00 price target on shares of Viridian Therapeutics in a research note on Tuesday, February 7th.
Viridian Therapeutics Price Performance
Viridian Therapeutics stock opened at $32.76 on Wednesday. The company has a current ratio of 17.35, a quick ratio of 17.35 and a debt-to-equity ratio of 0.02. The stock has a market cap of $932.35 million, a P/E ratio of -7.76 and a beta of 0.99. The company has a 50-day moving average price of $33.36 and a 200 day moving average price of $26.18. Viridian Therapeutics has a 12-month low of $9.47 and a 12-month high of $39.00.
Insider Buying and Selling at Viridian Therapeutics
Institutional Trading of Viridian Therapeutics
Several hedge funds have recently made changes to their positions in VRDN. Voya Investment Management LLC increased its stake in shares of Viridian Therapeutics by 37.2% during the fourth quarter. Voya Investment Management LLC now owns 14,297 shares of the company’s stock worth $418,000 after acquiring an additional 3,877 shares during the period. Alliancebernstein L.P. acquired a new stake in shares of Viridian Therapeutics in the 4th quarter valued at approximately $26,985,000. Chartwell Investment Partners LLC lifted its holdings in shares of Viridian Therapeutics by 6.1% in the 4th quarter. Chartwell Investment Partners LLC now owns 61,052 shares of the company’s stock valued at $1,784,000 after buying an additional 3,488 shares during the period. Metropolitan Life Insurance Co NY grew its holdings in Viridian Therapeutics by 47.0% during the fourth quarter. Metropolitan Life Insurance Co NY now owns 2,340 shares of the company’s stock worth $68,000 after acquiring an additional 748 shares during the period. Finally, MetLife Investment Management LLC raised its position in Viridian Therapeutics by 44.7% in the fourth quarter. MetLife Investment Management LLC now owns 19,843 shares of the company’s stock worth $580,000 after acquiring an additional 6,129 shares in the last quarter.
About Viridian Therapeutics
Viridian Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis.
- Get a free copy of the StockNews.com research report on Viridian Therapeutics (VRDN)
- Will Q4 Results Send Zoom Video Stock Higher?
- Is Amazon a Blue Chip Stock?
- Occidental Petroleum Pulls Back To The Sweet Spot
- Should You Take a Cruise in Royal Caribbean Stock?
- Is Target Stock Aiming For A Breakout In 2023?
Receive News & Ratings for Viridian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viridian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.